These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 1157247)

  • 41. Clofibrate and related compounds in hyperlipoproteinaemia. A review.
    Gustafson A
    Postgrad Med J; 1975; 51(8):66-71. PubMed ID: 768950
    [No Abstract]   [Full Text] [Related]  

  • 42. [Treatment of hyperlipoproteinaemia types IIa, IIb, IV and V with a combination of clofibrate and inositol nicotinate (author's transl)].
    Wilke H; Frahm H
    Dtsch Med Wochenschr; 1976 Mar; 101(11):401-5. PubMed ID: 1253701
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Drug therapy: antiplatelet therapy (second of two parts).
    Weiss HJ
    N Engl J Med; 1978 Jun; 298(25):1403-6. PubMed ID: 349388
    [No Abstract]   [Full Text] [Related]  

  • 44. Antiplatelet therapy (first of two parts).
    Weiss HJ
    N Engl J Med; 1978 Jun; 298(24):1344-7. PubMed ID: 651993
    [No Abstract]   [Full Text] [Related]  

  • 45. Effect of clofibrate on progression of coronary disease: a prospective angiographic study in man.
    Cohn K; Sakai FJ; Langston MF
    Am Heart J; 1975 May; 89(5):591-8. PubMed ID: 1091127
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Oral anticoagulants and platelet function in hypolipemic therapy using a new clofibrate analog (BM 15.075) (author's transl)].
    Zimmermann R; Hoffrichter A; Walter E; Ehlers W; Andrassy K; Lang PD; Schlierf G; Weber E; Barth P
    Dtsch Med Wochenschr; 1977 Apr; 102(14):509-12. PubMed ID: 852404
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Correlation of platelet survival time with occlusion of saphenous vein aorto-coronary bypass grafts.
    Steele P; Battock D; Pappas G; Genton E
    Circulation; 1976 Apr; 53(4):685-7. PubMed ID: 1082802
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Effect of sulfinpyrazone on the platelet function and in experimental thrombosis].
    Haas S; Ketterl R; Blümel G
    Fortschr Med; 1981 Jan; 99(4):113-8. PubMed ID: 7274948
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Treatment of primary hyperlipoproteinemia type IIb and IV. Comparison of the lipid lowering effect of phenformin, clofibrate, and a combination of both (author's transl)].
    Koschinsky T; Lenhard P; Gries FA; Vogelberg KH; Wolfram G; Lang PD; Vollmar J
    Med Klin; 1977 Sep; 72(38):1537-43. PubMed ID: 904549
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Clinical research into the hypolipemic and platelet antiaggregant activity of plafibride, Carried out in double-blind conditions and in comparison with clofibrate.
    Palmieri B; Gasparini Casari M; DiBlasio P; Zirilli E
    Arzneimittelforschung; 1981; 31(10a):1863-6. PubMed ID: 7032534
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Type IV hyperlipoproteinemia. Clofibrate without dietary therapy.
    Zelis R; Amsterdam EA; Spann JF; Mason DT
    JAMA; 1972 Oct; 222(3):326-8. PubMed ID: 4566727
    [No Abstract]   [Full Text] [Related]  

  • 52. Effects of clofibrate and a fat-modified diet on serum lipids.
    Brown HB; Lewis LA; Page IH
    Clin Pharmacol Ther; 1975 Feb; 17(2):171-8. PubMed ID: 164312
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Long-term treatment of hyperlipidemic patients with clofibrate.
    Berkowitz D
    JAMA; 1971 Nov; 218(7):1002-5. PubMed ID: 5000568
    [No Abstract]   [Full Text] [Related]  

  • 54. [Anti-platelet-aggregating drugs. Clinical pharmacology and therapeutic use].
    Croveri G
    Minerva Cardioangiol; 1980 Oct; 28(10):723-6. PubMed ID: 7465066
    [No Abstract]   [Full Text] [Related]  

  • 55. Anticoagulants and platelet-active agents in the secondary prevention of coronary artery disease.
    Van Aken WG
    Adv Cardiol; 1982; 31():98-101. PubMed ID: 6758512
    [No Abstract]   [Full Text] [Related]  

  • 56. Effects of heparin and clofibrate on blood-serum lipid levels in patients with ischaemic heart disease.
    Haviar V; Riecanský L; Kusá O; Luknárová O
    Cor Vasa; 1972; 14(3):188-96. PubMed ID: 4344417
    [No Abstract]   [Full Text] [Related]  

  • 57. Comparison of clofibrate with halofenate in diabetics with hyperlipidaemia.
    Krut LH; Seftel HC; Joffe BI
    S Afr Med J; 1977 Mar; 51(11):348-52. PubMed ID: 323994
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Clofibrate in coronary heart disease. Effect on morbidity and mortality.
    Krasno LR; Kidera GJ
    JAMA; 1972 Feb; 219(7):845-51. PubMed ID: 5066667
    [No Abstract]   [Full Text] [Related]  

  • 59. [Clinical application and evaluation of anti-platelet agents].
    Yasunaga K
    Nihon Rinsho; 1978 Dec; 36(12):3884-94. PubMed ID: 372628
    [No Abstract]   [Full Text] [Related]  

  • 60. Control of clofibrate toxicity in uremic hypertriglyceridemia.
    Goldberg AP; Sherrard DJ; Haas LB; Brunzell JD
    Clin Pharmacol Ther; 1977 Mar; 21(3):317-25. PubMed ID: 837651
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.